Iain Mackay - GSK Plc CFO - Designate, Executive Director
| GLAXF Stock | USD 19.81 0.20 1.00% |
Director
Mr. Iain James Mackay was Chief Financial Officer, Executive Director of the Company., effective May 2019. Prior to joining GSK, Iain was Group Finance Director at the global bank HSBC Holdings plc, a position he held for eight years. A chartered accountant, Iain has worked in Asia, the US and Europe and before HSBC was at General Electric, Schlumberger Dowell and Price Waterhouse Iain is a Trustee of the British Heart Foundation and a member of the Court of the University of Aberdeen. Iain holds an MA in Business Studies and Accounting, and an Honorary Doctorate from Aberdeen University in Scotland. since 2019.
| Age | 61 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Phone | 44 20 8047 5000 |
| Web | https://www.gsk.com |
GSK Plc Management Efficiency
The company has return on total asset (ROA) of 0.0659 % which means that it generated a profit of $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3131 %, meaning that it generated $0.3131 on every $100 dollars invested by stockholders. GSK Plc's management efficiency ratios could be used to measure how well GSK Plc manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Marc Dunoyer | AstraZeneca PLC ADR | 72 | |
| Frans Houten | Novartis AG ADR | 61 | |
| Susan DesmondHellmann | Pfizer Inc | 63 | |
| Manuel Medina | Bristol Myers Squibb | 53 | |
| Philip Broadley | AstraZeneca PLC ADR | 52 | |
| Yukio Tani | Ono Pharmaceutical Co | N/A | |
| Helen Hobbs | Pfizer Inc | 68 | |
| Genevieve Berger | AstraZeneca PLC ADR | 64 | |
| Julia Haller | Bristol Myers Squibb | 66 | |
| Toshihiro Tsujinaka | Ono Pharmaceutical Co | 59 | |
| Graham Chipchase | AstraZeneca PLC ADR | 54 | |
| Robert Bertolini | Bristol Myers Squibb | 58 | |
| Simon Moroney | Novartis AG ADR | 62 | |
| Toichi Takino | Ono Pharmaceutical Co | 55 | |
| Ann Fudge | Novartis AG ADR | 70 | |
| Satoshi Suzuki | Santen Pharmaceutical Co | N/A | |
| Karen Vousden | Bristol Myers Squibb | 63 | |
| Giri Ramsingh | Gilead Sciences | N/A | |
| James Quincey | Pfizer Inc | 56 | |
| Andreas Planta | Novartis AG ADR | 65 | |
| Peter Arduini | Bristol Myers Squibb | 56 | |
Management Performance
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 |
GSK plc Leadership Team
Elected by the shareholders, the GSK Plc's board of directors comprises two types of representatives: GSK Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GSK. The board's role is to monitor GSK Plc's management team and ensure that shareholders' interests are well served. GSK Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GSK Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Redfern, Chief Strategy Officer | ||
| Diana Conrad, Chief Officer | ||
| Emma Walmsley, President - Consumer Healthcare Worldwide | ||
| Sally Jackson, VP Office | ||
| Iain Mackay, CFO - Designate, Executive Director | ||
| James Ford, Senior Vice President General Counsel | ||
| Shobie Ramakrishnan, Chief Officer | ||
| Sarah EltonFarr, Head Relations | ||
| Julie Brown, Chief Officer | ||
| Tony Wood, Chief Officer |
GSK Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is GSK Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 90.86 B | |||
| Shares Outstanding | 4.09 B | |||
| Shares Owned By Insiders | 0.60 % | |||
| Shares Owned By Institutions | 41.06 % | |||
| Price To Earning | 11.44 X | |||
| Price To Book | 6.49 X |
Currently Active Assets on Macroaxis
Other Information on Investing in GSK Pink Sheet
GSK Plc financial ratios help investors to determine whether GSK Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GSK with respect to the benefits of owning GSK Plc security.